For & Against

Claude View

What's Next

The window that matters is narrow. Today is April 17, 2026. Genpact historically reports Q1 in the first week of May (Q1'25 dropped May 1); the Q1'26 call is the first test of whether management re-opens the bookings conversation after quietly dropping a $200M YoY decline into the 10-K footnotes. The stock has round-tripped from $50 (April 2025) to a fresh 52-week low of $34.18 on April 10, 2026 — a 32% drawdown into the print. What the market is actually asking is narrow: is ATS still compounding at 17%+, or has the AI pivot already decelerated before it crossed 30% of revenue?

No Results
No Results

Sell-side estimates for FY26 sit at $5.43B revenue (6.8% growth) and $3.59 EPS (14.7% growth) — a modest step-up from FY25's 6.6% / 11% actuals. At $36.65, the stock is priced as if ATS decelerates to low-teens and margins stall, which is a low bar that management has cleared every quarter under Kalra. The catalyst isn't exotic; it's a clean Q1 print with bookings back on the headline and ATS at 17%+.

For / Against / My View

For

Against

My View

Close call, slight edge to the bulls at this price — but it is the price doing the work, not the fundamentals. At $36.65 with 11.6% FCF yield, a 10x forward P/E, Nalanda sitting patient, and Kalra having rebuilt guidance credibility, I'd lean cautiously long into the Q1'26 print, but with the understanding that this is a mispricing trade (close the peer gap to EXLS) rather than a secular compounder story. The item that tips the scale: Quant's chart of G at 1.44x EV/Sales vs EXLS at 2.43x with faster growth is not explainable by fundamentals alone — it is explainable by skepticism about ATS durability, and that skepticism has a testable expiration date in two weeks. What would flip me to the Against side: any Q1 print that shows ATS below 15% growth, or a second consecutive year of bookings decline disclosed on the call rather than buried in the K. That single data point makes Warren's giveback math the dominant read and resets the multiple lower — there is no version of this thesis where you own a 10x stock whose forward growth rate is actually 4%.